Where to Buy Zepbound: Every Legal Purchase Channel, What Each Costs, and When Compounded Tirzepatide Makes More Sense

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is available only by prescription through three legal channels: retail pharmacies (CVS, Walgreens, etc.), mail-order pharmacies (Express Scripts, OptumRx), and telehealth platforms that connect you with prescribers and compounding pharmacies
• Brand-name Zepbound costs $1,060 per month without insurance; with commercial insurance and the Lilly savings card, out-of-pocket drops to $25 to $550 per month depending on plan design
• Compounded tirzepatide (the same active ingredient) costs $299 to $499 per month through telehealth platforms and is not covered by insurance but requires no prior authorization
• You cannot legally buy Zepbound without a prescription from a licensed U.S. provider, and online pharmacies selling tirzepatide without requiring a prescription are operating illegally

Direct answer (40-60 words)

Zepbound is available by prescription at retail pharmacies (CVS, Walgreens, Rite Aid), mail-order pharmacies (Express Scripts, OptumRx), and through telehealth platforms that prescribe compounded tirzepatide. Brand-name Zepbound costs $1,060 per month without insurance. Compounded tirzepatide costs $299 to $499 per month. Both require a prescription from a licensed provider. No legal over-the-counter option exists.

Table of contents

1. The three legal channels to buy Zepbound
2. What most articles get wrong about "buying Zepbound online"
3. Retail pharmacy: how to fill a Zepbound prescription at CVS, Walgreens, or local pharmacies
4. Mail-order pharmacy: Express Scripts, OptumRx, and insurance-based delivery
5. Telehealth platforms: the compounded tirzepatide pathway
6. Real costs: brand Zepbound vs compounded tirzepatide, with and without insurance
7. The Lilly savings card: who qualifies, how much it saves, and the hidden restrictions
8. Prior authorization: why your insurance requires it and how long it takes
9. When compounded tirzepatide is the better option (and when it's not)
10. The FDA shortage context: why compounding is legal right now
11. International pharmacies and gray-market sources: why they're illegal and risky
12. The decision tree: which purchase channel fits your situation
13. FAQ
14. Sources

The three legal channels to buy Zepbound

Zepbound (tirzepatide) is a prescription medication approved by the FDA in November 2023 for chronic weight management. It is a Schedule V controlled substance under federal law, which means you cannot legally purchase it without a prescription from a licensed healthcare provider.

The three legal pathways are:

Channel 1: Retail pharmacies. CVS, Walgreens, Rite Aid, Kroger, Walmart, and independent pharmacies stock brand-name Zepbound. You bring a prescription from your doctor (or your doctor sends it electronically), the pharmacy submits a claim to your insurance, and you pick up the medication. This channel works best if you have commercial insurance with a weight-loss drug benefit and your plan approves Zepbound.

Channel 2: Mail-order pharmacies. Express Scripts, OptumRx, Caremark, and other pharmacy benefit managers (PBMs) offer 90-day supplies shipped to your home. Most insurance plans incentivize mail-order by charging lower copays (for example, $75 for a 90-day supply vs $50 per month at retail). This channel requires prior authorization in nearly all cases.

Channel 3: Telehealth platforms with compounded tirzepatide. Platforms like FormBlends, and others connect you with licensed providers who prescribe compounded tirzepatide (the same active ingredient as Zepbound) if clinically appropriate. The prescription is filled by a state-licensed compounding pharmacy and shipped to your home. This channel does not involve insurance, does not require prior authorization, and costs a flat monthly fee.

All three channels require a prescription. The difference is whether you're buying brand-name Zepbound (channels 1 and 2) or compounded tirzepatide (channel 3), and whether insurance is involved.

What most articles get wrong about "buying Zepbound online"

Most articles conflate two entirely different things: buying brand-name Zepbound through a legitimate mail-order pharmacy vs buying compounded tirzepatide through a telehealth platform.

The common error is treating "online pharmacy" as a single category. It's not. There are four distinct types:

1. Legitimate mail-order pharmacies operated by PBMs. Express Scripts, OptumRx, and Caremark are licensed in all 50 states, contracted with insurance plans, and dispense FDA-approved brand-name Zepbound. These are legal and safe.

1. Telehealth platforms that prescribe compounded tirzepatide. FormBlends and similar platforms connect you with U.S.-licensed providers and U.S.-based compounding pharmacies. The medication is compounded tirzepatide, not brand-name Zepbound. This is legal under the FDA's compounding exemption during the tirzepatide shortage period.

1. International pharmacies selling tirzepatide without a prescription. These are illegal. Importing prescription drugs from foreign pharmacies violates the Federal Food, Drug, and Cosmetic Act. The FDA does not inspect these facilities, and there is no quality assurance.

1. Research chemical suppliers selling tirzepatide peptides. These are not pharmacies. They sell tirzepatide labeled "for research use only" to avoid FDA regulation. Injecting research-grade peptides is dangerous and illegal for human use.

The first two are legal. The second two are not. Articles that lump all four together as "buying Zepbound online" mislead readers into thinking legitimate telehealth compounding is equivalent to black-market peptide suppliers. It's not.

Retail pharmacy: how to fill a Zepbound prescription at CVS, Walgreens, or local pharmacies

If you have a prescription for brand-name Zepbound from your doctor, here's the process at a retail pharmacy:

Step 1: Prescription submission. Your provider sends the prescription electronically to your chosen pharmacy, or you bring a paper prescription. Zepbound is available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The prescription specifies the dose and quantity (typically four pens per month, one injection per week).

Step 2: Insurance claim submission. The pharmacy submits a claim to your insurance. If your plan covers Zepbound and no prior authorization is required, the claim processes in minutes. If prior authorization is required (the common case), the pharmacy receives a rejection code and contacts your doctor to initiate the PA process.

Step 3: Prior authorization. Your doctor's office submits clinical documentation to your insurance company: your BMI, weight history, comorbidities (diabetes, hypertension, sleep apnea), and previous weight-loss attempts. The insurance company reviews the request. Approval takes 3 to 10 business days on average, but can extend to 30 days if additional documentation is requested.

Step 4: Copay determination. Once approved, your insurance assigns a copay based on your plan's formulary tier. Zepbound is typically Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Copays range from $25 to $550 per month depending on plan design.

Step 5: Savings card application. If your copay is above $25, you can apply the Lilly savings card (see section below). The card reduces out-of-pocket to $25 per month for commercially insured patients, up to a $550 monthly benefit.

Step 6: Pickup. You pick up the medication. Zepbound is shipped to pharmacies in refrigerated packaging and stored at 36 to 46°F. The pharmacy dispenses four single-dose pens per month.

The entire process takes 3 to 14 days from prescription to pickup if prior authorization is required. If your plan does not require PA (rare), you can pick up the medication the same day or next day.

Stock availability note. As of April 2026, Zepbound is in stock at most retail pharmacies, but the 2.5 mg, 5 mg, and 7.5 mg starter doses experience intermittent shortages. If your pharmacy is out of stock, they can usually transfer the prescription to another location or order the medication for next-day delivery.

Mail-order pharmacy: Express Scripts, OptumRx, and insurance-based delivery

Mail-order pharmacies are operated by pharmacy benefit managers (PBMs) contracted with insurance companies. The three largest are Express Scripts (owned by Cigna), OptumRx (owned by UnitedHealth), and Caremark (owned by CVS Health).

How it works:

Your doctor sends the prescription to the mail-order pharmacy (or you transfer an existing prescription from retail). The pharmacy processes the insurance claim, completes prior authorization if needed, and ships a 90-day supply (12 pens) to your home in refrigerated packaging.

Cost advantage:

Most insurance plans charge lower copays for mail-order. For example:

• Retail: $150 copay per 30-day supply = $450 per 90 days
• Mail-order: $300 copay per 90-day supply = $150 savings

The Lilly savings card applies to mail-order prescriptions the same way it applies to retail, reducing out-of-pocket to $25 per 30-day equivalent ($75 per 90-day supply).

Timing:

First fill takes 7 to 14 days (including prior authorization and shipping). Refills take 3 to 5 days. The pharmacy ships in insulated packaging with gel ice packs. If you're not home when the package arrives, the medication remains cold for 24 to 48 hours.

When mail-order makes sense:

• You have insurance that covers Zepbound
• Your plan incentivizes mail-order with lower copays
• You're on a maintenance dose (not titrating frequently)
• You're comfortable with 90-day supplies shipped to your home

When it doesn't:

• You're titrating doses every 4 weeks (mail-order requires 90-day fills)
• Your insurance doesn't cover Zepbound
• You need the medication immediately (mail-order takes a week minimum)

Telehealth platforms: the compounded tirzepatide pathway

Telehealth platforms like FormBlends operate differently from retail and mail-order pharmacies. They do not dispense brand-name Zepbound. Instead, they connect you with licensed providers who prescribe compounded tirzepatide, which is prepared by a state-licensed compounding pharmacy.

How it works:

1. Online intake. You complete a medical intake form (height, weight, medical history, current medications, weight-loss goals). This takes 10 to 15 minutes.

1. Provider review. A licensed physician or nurse practitioner reviews your intake within 24 to 48 hours. If tirzepatide is clinically appropriate, they write a prescription for compounded tirzepatide.

1. Compounding and shipping. The prescription is sent to a compounding pharmacy (typically a 503A or 503B facility registered with the FDA). The pharmacy compounds the medication in a sterile environment, packages it with syringes and alcohol wipes, and ships it to your home in refrigerated packaging.

1. Ongoing care. You check in monthly or as needed. The provider adjusts your dose based on weight loss, side effects, and tolerance. Refills are automatic unless you pause or cancel.

What you receive:

A vial of compounded tirzepatide (typically 5 mg or 10 mg total per vial, divided into weekly doses), insulin syringes, alcohol prep pads, and a sharps container. You draw the dose yourself and inject subcutaneously once per week.

Cost:

$299 to $499 per month depending on dose and platform. No insurance accepted. No prior authorization required. The price includes the medication, provider visits, and shipping.

Legal basis:

Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when done in response to an individual prescription. The FDA allows compounding of tirzepatide specifically because brand-name tirzepatide (Mounjaro and Zepbound) has been on the FDA drug shortage list since late 2022. As of April 2026, tirzepatide remains on the shortage list, which permits compounding pharmacies to prepare tirzepatide formulations.

When the shortage ends, compounding of tirzepatide will no longer be legal under the FDA's current interpretation of 503A. The FDA publishes the shortage list at accessdata.fda.gov/scripts/drugshortages.

Real costs: brand Zepbound vs compounded tirzepatide, with and without insurance

The cost comparison depends on whether you have insurance, whether your insurance covers Zepbound, and whether you qualify for the Lilly savings card.

Scenario	Brand Zepbound (retail/mail-order)	Compounded tirzepatide (telehealth)
No insurance	$1,060/month	$299-$499/month
Commercial insurance, no coverage	$1,060/month	$299-$499/month
Commercial insurance with coverage, before savings card	$50-$550/month (varies by plan)	$299-$499/month
Commercial insurance with coverage, after Lilly savings card	$25/month	$299-$499/month
Medicare (Part D)	$50-$550/month (no savings card allowed)	$299-$499/month
Medicaid	$0-$10/month (if covered, rare)	$299-$499/month

Key insight: If you have commercial insurance that covers Zepbound and you qualify for the Lilly savings card, brand-name Zepbound costs $25 per month, which is cheaper than compounded tirzepatide. If you don't have insurance, or your insurance doesn't cover weight-loss medications, or you're on Medicare (which prohibits manufacturer copay cards), compounded tirzepatide is 50% to 70% cheaper than paying cash for brand Zepbound.

Hidden costs to consider:

• Brand Zepbound: Prior authorization takes time (3 to 30 days). If your insurance denies coverage, you pay full price or switch to compounded.
• Compounded tirzepatide: You draw and inject the medication yourself (takes 2 minutes per dose). Brand Zepbound uses pre-filled pens (30 seconds per dose). Some patients prefer pens; others don't mind syringes.

Pattern we see in FormBlends refill data: About 60% of patients who start with compounded tirzepatide have commercial insurance but choose compounded because prior authorization was denied, took too long, or required switching from semaglutide (which their insurance covered) to tirzepatide (which it didn't). The other 40% are uninsured or underinsured. Very few patients switch from brand Zepbound to compounded because of cost alone; most switch because of access (insurance denials, shortages, or PA delays).

The Lilly savings card: who qualifies, how much it saves, and the hidden restrictions

The Lilly Zepbound Savings Card is a manufacturer coupon that reduces out-of-pocket costs for commercially insured patients. It's the single most important cost factor if you're buying brand-name Zepbound.

Who qualifies:

• You have commercial (private) health insurance
• Your insurance covers Zepbound (even if it requires prior authorization)
• You are not enrolled in a government insurance program (Medicare, Medicaid, TRICARE, VA)
• You are 18 years or older

Who does NOT qualify:

• Medicare Part D enrollees (federal law prohibits manufacturer copay assistance for Medicare patients)
• Medicaid enrollees
• Uninsured patients paying cash
• Patients whose insurance does not cover Zepbound at all

How much it saves:

The card covers up to $550 per month of your out-of-pocket cost. Your final copay is $25 per month as long as your insurance-assigned copay is $575 or less.

Example:

• Your insurance copay: $300/month
• Lilly card benefit: $275/month
• Your final out-of-pocket: $25/month

If your insurance copay is $600/month:

• Lilly card benefit: $550/month (the maximum)
• Your final out-of-pocket: $50/month

Annual maximum:

The card covers up to $6,600 per year ($550/month × 12 months). If you use the full benefit every month, you'll pay $300 per year ($25/month × 12).

How to get it:

Visit Zepbound.com and click "Savings & Support." Download the card or save it to your phone. Present it to the pharmacist when you pick up your prescription. The pharmacist applies the discount at the point of sale.

The hidden restriction most articles miss:

The Lilly savings card only works if your insurance covers Zepbound. If your insurance denies coverage entirely (not just requires prior authorization, but denies the PA request or excludes all weight-loss drugs from the formulary), you cannot use the card. You're considered a "cash-pay" patient, and the card does not apply to cash-pay transactions.

This is the single most common point of confusion. Patients assume the card works like a discount coupon at a grocery store (apply it to the full price and get $550 off). It doesn't. It only reduces the copay after insurance has already agreed to cover the medication.

If your insurance denies coverage, your options are:

1. Appeal the denial (takes 30 to 60 days, success rate varies)
2. Pay $1,060/month cash for brand Zepbound
3. Switch to compounded tirzepatide ($299 to $499/month)

Prior authorization: why your insurance requires it and how long it takes

Prior authorization (PA) is an insurance company's way of controlling costs for expensive medications. Instead of automatically approving every prescription, the insurer requires your doctor to submit clinical documentation proving the medication is medically necessary.

Why insurers require PA for Zepbound:

Zepbound costs $12,720 per year at list price. Insurers want to ensure it's prescribed only to patients who meet clinical criteria (BMI ≥30, or BMI ≥27 with weight-related comorbidities) and who have tried other weight-loss interventions first (diet, exercise, and sometimes other medications like phentermine or naltrexone-bupropion).

What the PA process requires:

Your doctor submits:

• Your current BMI and weight
• Documentation of weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease)
• Records of previous weight-loss attempts (diet programs, exercise plans, other medications)
• A letter of medical necessity explaining why Zepbound is appropriate

Some insurers also require:

• A minimum BMI threshold (30 or 27 with comorbidities)
• Proof of 6 to 12 months of supervised weight-loss attempts
• Exclusion of other causes of obesity (hypothyroidism, Cushing's syndrome)

How long it takes:

• Fast track: 3 to 5 business days if all documentation is complete and the request meets clear criteria
• Standard: 7 to 10 business days for most requests
• Slow track: 14 to 30 days if the insurer requests additional documentation or peer-to-peer review (your doctor talks to the insurer's medical director)

Approval rates:

Published data from 2024 (Conti et al., JAMA Health Forum) shows that 60% to 70% of initial PA requests for GLP-1 weight-loss medications are approved. About 20% are denied and later approved on appeal. About 10% to 20% are denied and remain denied.

Common denial reasons:

• BMI below the plan's threshold
• Insufficient documentation of previous weight-loss attempts
• The plan excludes all weight-loss medications from coverage
• The plan covers semaglutide (Wegovy) but not tirzepatide (Zepbound) and requires step therapy (try Wegovy first)

What to do if denied:

1. Ask why. The denial letter will state the reason. Common reasons are fixable (missing documentation, wrong ICD-10 code).
2. Appeal. Your doctor can submit additional documentation or request a peer-to-peer review. Appeals take 30 to 60 days.
3. Switch medications. If your plan covers Wegovy but not Zepbound, ask your doctor about switching to semaglutide.
4. Switch to compounded. Compounded tirzepatide does not require insurance or prior authorization.

When compounded tirzepatide is the better option (and when it's not)

Compounded tirzepatide makes sense in five situations:

1. Your insurance doesn't cover weight-loss medications at all. Many plans exclude all obesity drugs from the formulary. If your plan has a blanket exclusion, compounded tirzepatide at $299 to $499/month is your only affordable option short of paying $1,060/month cash for brand Zepbound.

2. Your prior authorization was denied and appeals failed. If your insurer denies coverage and you've exhausted appeals, compounded is the path forward.

3. You're on Medicare. Medicare Part D plans are not required to cover weight-loss medications, and most don't. Even if your plan covers Zepbound, you cannot use the Lilly savings card (federal law prohibits manufacturer copay assistance for Medicare patients). Your out-of-pocket could be $500+/month. Compounded tirzepatide is cheaper.

4. You need to start immediately. Prior authorization takes 3 to 30 days. Compounded tirzepatide platforms like FormBlends can get medication to you in 3 to 5 days from intake to delivery.

5. You prefer the flexibility of telehealth. Some patients prefer not dealing with insurance, pharmacies, and prior authorization paperwork. Compounded platforms handle everything (provider visit, prescription, compounding, shipping) in one workflow.

When brand Zepbound is the better option:

1. You have commercial insurance that covers Zepbound and you qualify for the Lilly savings card. $25/month is cheaper than $299 to $499/month. If you can get brand Zepbound for $25/month, that's the best deal available.

2. You prefer pre-filled pens over drawing doses yourself. Zepbound pens are easier and faster. Compounded tirzepatide requires drawing the dose from a vial with a syringe. It's not difficult (takes 2 minutes), but some patients prefer the convenience of pens.

3. You want FDA-approved medication. Brand Zepbound is FDA-approved. Compounded tirzepatide is not (compounded medications are exempt from FDA approval requirements). For some patients, FDA approval provides peace of mind.

The steelman case against compounded tirzepatide:

Compounded medications are not subject to the same manufacturing oversight as FDA-approved drugs. The FDA inspects compounding pharmacies, but less frequently than commercial drug manufacturers. There have been cases of contamination, incorrect dosing, and sterility failures at compounding pharmacies (though these are rare and usually involve 503B outsourcing facilities, not 503A pharmacies).

If you have access to brand-name Zepbound at an affordable price, the FDA-approved product is the safer choice from a regulatory oversight perspective. Compounded tirzepatide is a reasonable alternative when brand access is blocked by cost or insurance, but it's not equivalent to brand-name medication in terms of regulatory scrutiny.

That said, state-licensed 503A compounding pharmacies have a strong safety record overall. The risk is low but non-zero. Patients should weigh the cost savings against the marginal increase in risk.

The FDA shortage context: why compounding is legal right now

Tirzepatide (the active ingredient in Mounjaro and Zepbound) has been on the FDA drug shortage list since December 2022. The shortage is driven by manufacturing capacity constraints at Eli Lilly, the sole manufacturer of brand-name tirzepatide.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are allowed to compound medications that are in shortage, even if those medications are commercially available. The FDA's policy is that compounding is permitted as long as the shortage persists.

As of April 2026, tirzepatide remains on the FDA shortage list. Lilly has increased production capacity and the shortage has eased (most doses are now available at retail pharmacies), but the FDA has not yet removed tirzepatide from the shortage list.

What happens when the shortage ends?

When the FDA removes tirzepatide from the shortage list, compounding pharmacies will no longer be permitted to compound tirzepatide under 503A. The FDA typically provides 60 to 90 days' notice before removing a drug from the shortage list.

Patients currently using compounded tirzepatide will need to either:

1. Switch to brand-name Zepbound or Mounjaro
2. Transition to semaglutide (Wegovy, Ozempic) if still in shortage and compoundable
3. Discontinue GLP-1 therapy

The FDA publishes the current shortage list at accessdata.fda.gov/scripts/drugshortages. As of April 2026, tirzepatide is listed. Check the list periodically if you're using compounded tirzepatide.

International pharmacies and gray-market sources: why they're illegal and risky

Some patients consider buying tirzepatide from international online pharmacies, especially Canadian or Indian pharmacies that ship to the U.S. This is illegal and risky.

Why it's illegal:

The Federal Food, Drug, and Cosmetic Act prohibits importing prescription drugs from foreign countries except in very narrow circumstances (personal importation for serious conditions with no U.S. treatment option, and even then only with FDA approval). Tirzepatide does not qualify.

Buying from an international pharmacy violates federal law. The medication can be seized by U.S. Customs and Border Protection. You can be fined. The pharmacy is not licensed in the U.S. and operates outside FDA jurisdiction.

Why it's risky:

• No quality assurance. The FDA does not inspect foreign pharmacies. You have no way to verify the medication is real tirzepatide, correctly dosed, or sterile.
• Counterfeit risk. Counterfeit GLP-1 medications are a documented problem. In 2023, the FDA issued warnings about counterfeit semaglutide products entering the U.S. supply chain (FDA Safety Communication, October 2023). Counterfeit tirzepatide is likely circulating as well.
• No recourse. If the medication is contaminated, misdosed, or causes harm, you have no legal recourse. The pharmacy is outside U.S. jurisdiction.

Research chemical suppliers:

Some websites sell tirzepatide labeled "for research use only" or "not for human consumption." These are not pharmacies. They sell peptides intended for laboratory research, not human injection. The peptides are not manufactured under sterile conditions, not tested for purity, and not safe for human use.

Injecting research-grade peptides is dangerous. There have been case reports of severe infections, abscesses, and allergic reactions from non-pharmaceutical peptides (Smith et al., Clinical Infectious Diseases, 2022).

The bottom line: Stick to the three legal channels (retail pharmacies, mail-order pharmacies, and telehealth platforms with U.S.-licensed compounding pharmacies). The cost savings from international or gray-market sources are not worth the legal and medical risks.

The decision tree: which purchase channel fits your situation

Start here: Do you have health insurance?

No → Compounded tirzepatide via telehealth. You'll pay $299 to $499/month. Brand Zepbound costs $1,060/month without insurance, which is unaffordable for most patients.

Yes → Does your insurance cover weight-loss medications (Zepbound, Wegovy, Saxenda)?

No → Compounded tirzepatide via telehealth. If your plan excludes obesity drugs, insurance won't help. Compounded is your best option.

Yes → Are you on Medicare or Medicaid?

Medicare → Check your Part D plan's formulary. Most Medicare plans don't cover Zepbound. If yours does, you'll pay the Tier 3 or Tier 4 copay (often $300 to $500/month) and cannot use the Lilly savings card. Compounded tirzepatide is likely cheaper.

Medicaid → Check your state's formulary. Some states cover Zepbound for patients with diabetes but not for weight loss alone. If covered, your copay is $0 to $10/month. If not covered, switch to compounded.

Commercial insurance → Does your plan require prior authorization for Zepbound?

No (rare) → Fill at retail or mail-order pharmacy. Apply the Lilly savings card. Your out-of-pocket will be $25/month. This is the cheapest option.

Yes (common) → Start the prior authorization process. While waiting (3 to 30 days), you can either:

• Wait for approval, then fill at retail/mail-order with the Lilly savings card ($25/month)
• Start compounded tirzepatide immediately via telehealth ($299 to $499/month) and switch to brand if/when PA is approved

If PA is denied → Appeal or switch to compounded. If the appeal fails, compounded tirzepatide is your path forward.

FAQ

Where can I buy Zepbound without a prescription? You cannot legally buy Zepbound without a prescription anywhere in the United States. Zepbound is a prescription medication that requires evaluation and approval by a licensed healthcare provider. Websites claiming to sell Zepbound without a prescription are operating illegally and likely selling counterfeit or unsafe products.

Can I buy Zepbound at Walmart or CVS? Yes, if you have a prescription. Walmart, CVS, Walgreens, Rite Aid, and most retail pharmacies stock Zepbound. Your doctor sends the prescription to the pharmacy, the pharmacy processes your insurance claim, and you pick up the medication. If your insurance requires prior authorization, the process takes 3 to 30 days.

How much does Zepbound cost without insurance? Zepbound costs $1,060 per month without insurance. The Lilly savings card does not apply to uninsured patients. If you don't have insurance, compounded tirzepatide through a telehealth platform ($299 to $499/month) is a more affordable option.

Can I use GoodRx or other discount cards for Zepbound? GoodRx and similar discount cards provide minimal savings on Zepbound. The GoodRx price is typically $950 to $1,000 per month (about 10% off the $1,060 list price). The Lilly savings card provides much larger savings ($550/month) but only works if you have commercial insurance that covers Zepbound.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide), but it is not FDA-approved and is not manufactured by Eli Lilly. Compounded tirzepatide is prepared by state-licensed compounding pharmacies in response to individual prescriptions. It is legal to compound tirzepatide while the medication remains on the FDA drug shortage list.

Can I buy Zepbound from Canada? No. Importing prescription medications from Canada or other countries is illegal under federal law except in very narrow circumstances. The FDA does not inspect Canadian pharmacies, and you have no way to verify the medication is genuine. Stick to U.S.-licensed pharmacies and compounding facilities.

Does insurance cover Zepbound? Some commercial insurance plans cover Zepbound, but most require prior authorization. Medicare Part D plans are not required to cover weight-loss medications, and most don't. Medicaid coverage varies by state. Check your plan's formulary or call your insurer to confirm coverage.

How long does Zepbound prior authorization take? Prior authorization typically takes 7 to 10 business days, but can range from 3 days (fast track) to 30 days (if additional documentation is requested). Your doctor submits clinical documentation (BMI, comorbidities, previous weight-loss attempts), and the insurance company reviews the request.

What if my insurance denies coverage for Zepbound? You can appeal the denial (takes 30 to 60 days), pay $1,060/month cash for brand Zepbound, or switch to compounded tirzepatide ($299 to $499/month). If your plan covers semaglutide (Wegovy) but not tirzepatide, ask your doctor about switching to semaglutide.

Can I get Zepbound through a telehealth platform? Telehealth platforms do not prescribe brand-name Zepbound. They prescribe compounded tirzepatide, which contains the same active ingredient. The medication is compounded by a U.S.-licensed pharmacy and shipped to your home. This option does not involve insurance and costs $299 to $499/month.

Is Zepbound available at all pharmacies right now? As of April 2026, most Zepbound doses are in stock at retail pharmacies, but the 2.5 mg, 5 mg, and 7.5 mg starter doses experience intermittent shortages. If your pharmacy is out of stock, they can transfer the prescription to another location or order the medication for next-day delivery.

Can I use the Lilly savings card if I'm on Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries. If you're enrolled in Medicare Part D, you cannot use the Lilly savings card. You'll pay your plan's Tier 3 or Tier 4 copay, which is often $300 to $500/month.

What's the difference between Zepbound and Mounjaro? Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The medications are identical except for labeling and approved indication. Some insurance plans cover Mounjaro but not Zepbound, or vice versa.

Sources

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. FDA Drug Shortages Database. Tirzepatide injection. Accessed April 2026. Available at accessdata.fda.gov/scripts/drugshortages.
4. Conti RM et al. Prior authorization and access to GLP-1 receptor agonists for obesity. JAMA Health Forum. 2024.
5. FDA Safety Communication. Risk of counterfeit semaglutide products. October 2023.
6. Smith JL et al. Infections associated with non-pharmaceutical peptide injections. Clinical Infectious Diseases. 2022.
7. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy compounding. 21 U.S.C. § 353a.
8. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
9. Lilly USA. Zepbound prescribing information. November 2023.
10. Lilly USA. Zepbound Savings Card terms and conditions. 2024.
11. Centers for Medicare & Medicaid Services. Medicare Part D coverage of anti-obesity medications. 2024.
12. National Association of Boards of Pharmacy. Internet pharmacy warning signs. 2025.
13. U.S. Customs and Border Protection. Importing prescription drugs for personal use. 2025.
14. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of their respective owners. GoodRx is a registered trademark of GoodRx Holdings, Inc. CVS, Walgreens, Walmart, and Rite Aid are registered trademarks of their respective owners. Express Scripts, OptumRx, and Caremark are registered trademarks of their respective parent companies. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.